ESTRO 2022 - Abstract Book

S1057

Abstract book

ESTRO 2022

Conclusion The present analysis demonstrated that in a cohort of inoperable stage III NSCLC patients treated with cCRT +/- ICI during the last decade, PTV>700cc, V20MED30, ≥ 20 pack-years and ICI are important prognosticators of survival outcome.

PO-1253 Lung metastases from different primary tumors treated with Stereotactic ablative radiotherapy

J.V. Rojas Cordero 1 , G. Sancho Pardo 2 , K. Majercakova 2 , P. Gallego Franco 3 , P. Carrasco de Fez 3 , A.M. Soto Cambres 4 , J. Balart Serra 2 , N. Farré Bernadó 2 1 Hospital Santa Creu i Sant Pau, Radiation Oncology, Barcelona, Spain; 2 Hospital de la Santa Creu i Sant Pau, Radiation Oncology, Barcelona, Spain; 3 Hospital de la Santa Creu i Sant Pau, Radiophysics, Barcelona, Spain; 4 Hospital de la Santa Creu i Sant pau, Radiation Oncology, Barcelona, Spain Purpose or Objective To evaluate the clinical efficacy of stereotactic ablative radiotherapy for all lung metastases from different primary tumors. Materials and Methods This is a restrospective study of patients with lung metastases from different primary tumor histologies treated with SABR between January 2013 and September 2020. Inclusion study criteria was: oligometastases, oligoprogression, oligopersistance, not suitable for surgery, maximum tumor diameter ≤ 50 mm and a maximum of 4 lung metastases. Pretreatment evaluation was performed with 18-F-FDG PET/CT scan. Histological confirmation was performed when feasible. Risk-adapted fractionation was used (5x11Gy,5x10 Gy,8x7.5Gy). Local control (LC), cancer specific survival (CSS)